NCT06380907View on ClinicalTrials.gov

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions
Plaque Psoriasis
Interventions
DRUG

ZL-1102 1% w/w gel BID for 16 weeks

"ZL-1102~1% w/w gel BID for 16 weeks"

DRUG

ZL-1102 3% w/w gel BID for 16 weeks

ZL-1102 3% w/w gel BID for 16 weeks

DRUG

ZL-1102 3% w/w gel QD for 16 weeks

ZL-1102 3% w/w gel QD for 16 weeks

DRUG

Placebo ZL-1102 0% w/w gel BID for 16 weeks

Vehicle 0% w/w gel BID for 16 weeks

DRUG

Placebo ZL-1102 0% w/w gel QD for 16 weeks

Vehicle 0% w/w gel QD for 16 weeks

Trial Locations (10)

2217

RECRUITING

Zai Lab Site 5021, Kogarah

2289

RECRUITING

Zai Lab Site 5016, Kotara

2606

RECRUITING

Zai Lab Site 5013, Phillip

3002

RECRUITING

Zai Lab Site 5002, Melbourne E.

3050

RECRUITING

Zai Lab Site 5018, Parkville

3053

RECRUITING

Zai Lab Site 5014, Carlton

3124

RECRUITING

Zai Lab Site 5015, Melbourne

4102

RECRUITING

Zai Lab Site 5017, Woolloongabba

4151

RECRUITING

Zai Lab Site 5019, Coorparoo

4375

RECRUITING

Zai Lab Site 5020, Birtinya

All Listed Sponsors
collaborator

Zai Lab (US) LLC

INDUSTRY

lead

Zai Lab (Hong Kong), Ltd.

INDUSTRY